| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Nov 2018 | Nov 2019 | Nov 2020 | Nov 2021 | Nov 2022 | Nov 2023 | Nov 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 37.45M | 31.11M | 17.82M | 29.75M | 38.63M | 76.99M | 54.55M |
| Revenue Growth % | - | -0.17% | -0.43% | 0.67% | 0.3% | 0.99% | -0.29% |
| Cost of Goods Sold | 40.51M | 45.02M | 66.49M | 116.43M | 184.5M | 189.15M | 221.63M |
| COGS % of Revenue | 1.08% | 1.45% | 3.73% | 3.91% | 4.78% | 2.46% | 4.06% |
| Gross Profit | -3.06M | -13.91M | -48.67M | -86.68M | -145.87M | -112.16M | -167.08M |
| Gross Margin % | -0.08% | -0.45% | -2.73% | -2.91% | -3.78% | -1.46% | -3.06% |
| Gross Profit Growth % | - | -3.54% | -2.5% | -0.78% | -0.68% | 0.23% | -0.49% |
| Operating Expenses | 6.67M | 8.33M | 16.31M | 31.2M | 38M | 42.9M | 45.94M |
| OpEx % of Revenue | 0.18% | 0.27% | 0.92% | 1.05% | 0.98% | 0.56% | 0.84% |
| Selling, General & Admin | 6.67M | 8.33M | 16.31M | 31.2M | 38M | 42.9M | 45.94M |
| SG&A % of Revenue | 0.18% | 0.27% | 0.92% | 1.05% | 0.98% | 0.56% | 0.84% |
| Research & Development | 40.51M | 45.02M | 66.49M | 116.43M | 184.5M | 189.15M | 221.63M |
| R&D % of Revenue | 1.08% | 1.45% | 3.73% | 3.91% | 4.78% | 2.46% | 4.06% |
| Other Operating Expenses | -40.51M | -45.02M | -66.49M | -116.43M | -184.5M | -189.15M | -221.63M |
| Operating Income | -9.74M | -22.24M | -64.98M | -117.89M | -183.87M | -155.06M | -213.03M |
| Operating Margin % | -0.26% | -0.71% | -3.65% | -3.96% | -4.76% | -2.01% | -3.91% |
| Operating Income Growth % | - | -1.28% | -1.92% | -0.81% | -0.56% | 0.16% | -0.37% |
| EBITDA | -6.75M | -19.88M | -62.8M | -115.9M | -179.72M | -148.93M | -205.01M |
| EBITDA Margin % | -0.18% | -0.64% | -3.52% | -3.9% | -4.65% | -1.93% | -3.76% |
| EBITDA Growth % | - | -1.95% | -2.16% | -0.85% | -0.55% | 0.17% | -0.38% |
| D&A (Non-Cash Add-back) | 2.99M | 2.35M | 2.18M | 1.99M | 4.15M | 6.13M | 8.02M |
| EBIT | -9.74M | -22.24M | -64.98M | -117.89M | -183.87M | -155.06M | -213.03M |
| Net Interest Income | 818K | 776K | 1.21M | 823K | 3.51M | 11.12M | 19.73M |
| Interest Income | 818K | 776K | 1.21M | 823K | 3.51M | 11.12M | 19.73M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 818K | 776K | 1.21M | 823K | 3.51M | 11.12M | 19.73M |
| Pretax Income | -8.92M | -21.46M | -63.78M | -117.06M | -180.36M | -143.95M | -193.3M |
| Pretax Margin % | -0.24% | -0.69% | -3.58% | -3.93% | -4.67% | -1.87% | -3.54% |
| Income Tax | 507K | 239K | -20.54M | 131K | 0 | 0 | 270K |
| Effective Tax Rate % | 1.06% | 1.01% | 0.68% | 1% | 1% | 1% | 1% |
| Net Income | -9.43M | -21.7M | -43.24M | -117.19M | -180.36M | -143.95M | -193.57M |
| Net Margin % | -0.25% | -0.7% | -2.43% | -3.94% | -4.67% | -1.87% | -3.55% |
| Net Income Growth % | - | -1.3% | -0.99% | -1.71% | -0.54% | 0.2% | -0.34% |
| Net Income (Continuing) | -9.43M | -21.7M | -43.24M | -117.19M | -180.36M | -143.95M | -193.57M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.59 | -0.56 | -2.76 | -2.73 | -3.71 | -2.65 | -2.88 |
| EPS Growth % | - | 0.05% | -3.93% | 0.01% | -0.36% | 0.29% | -0.09% |
| EPS (Basic) | -0.59 | -0.56 | -2.76 | -2.73 | -3.71 | -2.65 | -2.88 |
| Diluted Shares Outstanding | 16.11M | 38.85M | 15.67M | 42.9M | 48.61M | 54.34M | 67.12M |
| Basic Shares Outstanding | 16.11M | 38.85M | 15.67M | 42.9M | 48.61M | 54.34M | 67.12M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Nov 2018 | Nov 2019 | Nov 2020 | Nov 2021 | Nov 2022 | Nov 2023 | Nov 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 40.65M | 39.35M | 298.43M | 311.12M | 318.45M | 295.5M | 619.39M |
| Cash & Short-Term Investments | 39.04M | 37.72M | 281.15M | 295.72M | 309.14M | 287.91M | 609.58M |
| Cash Only | 25.59M | 34.82M | 119.36M | 80.51M | 64.47M | 54.63M | 110M |
| Short-Term Investments | 13.45M | 2.9M | 161.79M | 215.21M | 244.67M | 233.28M | 499.59M |
| Accounts Receivable | 0 | 0 | 11.35M | 6.2M | 1.1M | 800K | 1.5M |
| Days Sales Outstanding | - | - | 232.4 | 76.12 | 10.39 | 3.79 | 10.04 |
| Inventory | 0 | 0 | 0 | 0 | -1.1M | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 900K | 9.31M | 6.79M | 8.3M |
| Total Non-Current Assets | 4.74M | 4.69M | 97.91M | 165.65M | 98.31M | 60.09M | 49.96M |
| Property, Plant & Equipment | 4.42M | 3.87M | 6.67M | 25.34M | 29.51M | 47.95M | 45.9M |
| Fixed Asset Turnover | 8.47x | 8.04x | 2.67x | 1.17x | 1.31x | 1.61x | 1.19x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 170K | 506K | 90.89M | 137.47M | 63.88M | 7.42M | 0 |
| Other Non-Current Assets | 151K | 317K | 347K | 3.12M | 4.92M | 4.72M | 4.06M |
| Total Assets | 45.4M | 44.05M | 396.34M | 476.77M | 416.76M | 355.6M | 669.34M |
| Asset Turnover | 0.82x | 0.71x | 0.04x | 0.06x | 0.09x | 0.22x | 0.08x |
| Asset Growth % | - | -0.03% | 8% | 0.2% | -0.13% | -0.15% | 0.88% |
| Total Current Liabilities | 32.83M | 16.14M | 44.54M | 66.26M | 70.66M | 86.96M | 95.85M |
| Accounts Payable | 1.3M | 1.6M | 3.41M | 6.65M | 5.06M | 6.4M | 11.48M |
| Days Payables Outstanding | 11.69 | 12.95 | 18.73 | 20.85 | 10.02 | 12.35 | 18.91 |
| Short-Term Debt | 0 | 0 | 0 | 3.85M | 5.53M | 7.49M | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 726K | 1.18M | 2.6M | 5.67M | 9.14M | 751K | 18.91M |
| Current Ratio | 1.24x | 2.44x | 6.70x | 4.70x | 4.51x | 3.40x | 6.46x |
| Quick Ratio | 1.24x | 2.44x | 6.70x | 4.70x | 4.52x | 3.40x | 6.46x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 49.41M | 85.63M | 61.53M | 68.21M | 42.41M | 68.15M | 46.5M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 9.19M | 6.43M | 23.13M | 20.29M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.22M | 1.74M | 850K | 0 | 0 | 0 | 0 |
| Total Liabilities | 34.05M | 53.57M | 106.07M | 134.47M | 113.06M | 155.1M | 142.35M |
| Total Debt | 0 | 0 | 0 | 13.04M | 11.96M | 30.61M | 28.3M |
| Net Debt | -25.59M | -34.82M | -119.36M | -67.47M | -52.51M | -24.01M | -81.69M |
| Debt / Equity | - | - | - | 0.04x | 0.04x | 0.15x | 0.05x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - |
| Total Equity | -36.85M | -57.71M | 290.27M | 342.3M | 303.7M | 200.49M | 526.99M |
| Equity Growth % | - | -0.57% | 6.03% | 0.18% | -0.11% | -0.34% | 1.63% |
| Book Value per Share | -2.29 | -1.49 | 18.52 | 7.98 | 6.25 | 3.69 | 7.85 |
| Total Shareholders' Equity | -36.85M | -57.71M | 290.27M | 342.3M | 303.7M | 200.49M | 526.99M |
| Common Stock | 3K | 4K | 39K | 45K | 47K | 49K | 76K |
| Retained Earnings | -38.76M | -60.46M | -103.7M | -220.89M | -401.25M | -545.2M | -738.77M |
| Treasury Stock | -1.9M | -2.73M | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -4K | -2K | 87K | -608K | -4.32M | -655K | 150K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Nov 2018 | Nov 2019 | Nov 2020 | Nov 2021 | Nov 2022 | Nov 2023 | Nov 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -31.68M | 601K | -80K | -84.36M | -159.81M | -81.36M | -172.58M |
| Operating CF Margin % | -0.85% | 0.02% | -0% | -2.84% | -4.14% | -1.06% | -3.16% |
| Operating CF Growth % | - | 1.02% | -1.13% | -1053.56% | -0.89% | 0.49% | -1.12% |
| Net Income | -9.43M | -21.7M | -43.24M | -117.19M | -180.36M | -143.95M | -193.57M |
| Depreciation & Amortization | 2.99M | 2.35M | 2.18M | 6.08M | 10.81M | 13.65M | 16.43M |
| Stock-Based Compensation | 431K | 510K | 4.3M | 15.8M | 28.13M | 33.67M | 33.93M |
| Deferred Taxes | -354K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -6K | -109K | 273K | 1.83M | 636K | -4.87M | -10.97M |
| Working Capital Changes | -25.31M | 19.55M | 36.41M | 9.11M | -19.02M | 20.12M | -18.4M |
| Change in Receivables | 12.37M | 0 | -11.35M | -6M | 6M | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 6.77M | 0 | 0 | 0 |
| Change in Payables | -519K | 302K | 1.23M | 1.59M | 85K | 1.61M | 5.21M |
| Cash from Investing | 39.99M | 8.5M | -254.4M | -108.25M | 27.2M | 68.3M | -257.71M |
| Capital Expenditures | -1.59M | -1.65M | -4.55M | -5.66M | -12.24M | -8.4M | -9.27M |
| CapEx % of Revenue | 0.04% | 0.05% | 0.26% | 0.19% | 0.32% | 0.11% | 0.17% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 10.15M | -249.85M | -102.59M | 39.44M | 0 | 0 |
| Cash from Financing | 529K | 126K | 339.02M | 153.88M | 117.19M | 3.22M | 485.67M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | 963K | 3.73M | 97.79M | 0 | 7.17M |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -33.27M | -1.05M | -4.63M | -90.03M | -172.05M | -89.77M | -181.86M |
| FCF Margin % | -0.89% | -0.03% | -0.26% | -3.03% | -4.45% | -1.17% | -3.33% |
| FCF Growth % | - | 0.97% | -3.41% | -18.43% | -0.91% | 0.48% | -1.03% |
| FCF per Share | -2.07 | -0.03 | -0.30 | -2.10 | -3.54 | -1.65 | -2.71 |
| FCF Conversion (FCF/Net Income) | 3.36x | -0.03x | 0.00x | 0.72x | 0.89x | 0.57x | 0.89x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 1K | 1K | 1K | 481K | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -37.19% | -37.05% | -55.84% | -57.1% | -53.22% |
| Return on Invested Capital (ROIC) | - | - | -124.36% | -39.67% | -52.43% | -54.39% | -51.39% |
| Gross Margin | -8.18% | -44.71% | -273.14% | -291.37% | -377.64% | -145.69% | -306.3% |
| Net Margin | -25.18% | -69.74% | -242.66% | -393.93% | -466.93% | -186.98% | -354.85% |
| Debt / Equity | - | - | - | 0.04x | 0.04x | 0.15x | 0.05x |
| FCF Conversion | 3.36x | -0.03x | 0.00x | 0.72x | 0.89x | 0.57x | 0.89x |
| Revenue Growth | - | -16.91% | -42.73% | 66.95% | 29.84% | 99.31% | -29.15% |
| 2023 | 2024 | |
|---|---|---|
| Collaboration Revenue | 56.99M | 54.55M |
| Collaboration Revenue Growth | - | -4.28% |
| License Revenue | 20M | - |
| License Revenue Growth | - | - |
Nurix Therapeutics, Inc. (NRIX) reported $83.7M in revenue for fiscal year 2024. This represents a 123% increase from $37.4M in 2018.
Nurix Therapeutics, Inc. (NRIX) saw revenue decline by 29.1% over the past year.
Nurix Therapeutics, Inc. (NRIX) reported a net loss of $244.8M for fiscal year 2024.
Nurix Therapeutics, Inc. (NRIX) has a return on equity (ROE) of -53.2%. Negative ROE indicates the company is unprofitable.
Nurix Therapeutics, Inc. (NRIX) had negative free cash flow of $241.4M in fiscal year 2024, likely due to heavy capital investments.